Overexpression of α-enolase correlates with poor survival in canine mammary carcinoma

BMC Veterinary Research

Volumn 7, Issue , 2011, Pages

  Chu, Pei Yi ^a,b   Hsu, Nicholas C ^c   Liao, Albert T ^b   Shih, Neng Yao ^d   Hou, Ming Feng ^e   Liu, Chen Hsuan ^b  

^a St Martin De Porres Hospital   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^d NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^e KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; ENOLASE;

ANIMAL; ANIMAL DISEASE; ARTICLE; CHEMISTRY; DOG; DOG DISEASE; EXPERIMENTAL NEOPLASM; FEMALE; GENE EXPRESSION REGULATION; IMMUNOBLOTTING; METABOLISM; MORTALITY; UDDER;

ANIMALS; BIOLOGICAL MARKERS; DOG DISEASES; DOGS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; IMMUNOBLOTTING; MAMMARY GLANDS, ANIMAL; MAMMARY NEOPLASMS, ANIMAL; PHOSPHOPYRUVATE HYDRATASE;

EID: 80054757041     PISSN: None     EISSN: 17466148     Source Type: Journal    
DOI: 10.1186/1746-6148-7-62     Document Type: Article

References (39)

1. Cotchin E. Mammary neoplasms of the bitch. J Comp Pathol 1958, 68(1):1-22.
2. Moulton JE, Taylor DO, Dorn CR, Andersen AC. Canine mammary tumors. Pathol Vet 1970, 7(4):289-320. 10.1177/030098587000700401, 4328309.
3. Prier JE, Brodey RS. Canine Neoplasia. A Prototype for Human Cancer Study. Bull World Health Organ 1963, 29:331-344. 2554964, 14058226.
4. Gama A, Alves A, Schmitt F. Identification of molecular phenotypes in canine mammary carcinomas with clinical implications: application of the human classification. Virchows Arch 2008, 453(2):123-132. 10.1007/s00428-008-0644-3, 18677512.
5. Ferreira E, Gobbi H, Saraiva BS, Cassali GD. Columnar cell lesions of the canine mammary gland: pathological features and immunophenotypic analysis. BMC Cancer 2010, 10:61. 10.1186/1471-2407-10-61, 2841138, 20178635.
6. Mouser P, Miller MA, Antuofermo E, Badve SS, Mohammed SI. Prevalence and classification of spontaneous mammary intraepithelial lesions in dogs without clinical mammary disease. Vet Pathol 2010, 47(2):275-284. 10.1177/0300985809358603, 20106771.
7. Vinothini G, Balachandran C, Nagini S. Evaluation of molecular markers in canine mammary tumors: correlation with histological grading. Oncol Res 2009, 18(5-6):193-201.
8. Strandberg JD, Goodman DG. Animal model of human disease: canine mammary neoplasia. Am J Pathol 1974, 75(1):225-228. 1910803, 4825616.
9. Martin PM, Cotard M, Mialot JP, Andre F, Raynaud JP. Animal models for hormone-dependent human breast cancer. Relationship between steroid receptor profiles in canine and feline mammary tumors and survival rate. Cancer Chemother Pharmacol 1984, 12(1):13-17.
10. Pancholi V. Multifunctional alpha-enolase: its role in diseases. Cell Mol Life Sci 2001, 58(7):902-920. 10.1007/PL00000910, 11497239.
11. Jiang BH, Agani F, Passaniti A, Semenza GL. V-SRC induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: involvement of HIF-1 in tumor progression. Cancer Res 1997, 57(23):5328-5335.
12. Wygrecka M, Marsh LM, Morty RE, Henneke I, Guenther A, Lohmeyer J, Markart P, Preissner KT. Enolase-1 promotes plasminogen-mediated recruitment of monocytes to the acutely inflamed lung. Blood 2009, 113(22):5588-5598. 10.1182/blood-2008-08-170837, 19182206.
13. Arza B, Felez J, Lopez-Alemany R, Miles LA, Munoz-Canoves P. Identification of an epitope of alpha-enolase (a candidate plasminogen receptor) by phage display. Thromb Haemost 1997, 78(3):1097-1103.
14. Redlitz A, Fowler BJ, Plow EF, Miles LA. The role of an enolase-related molecule in plasminogen binding to cells. Eur J Biochem 1995, 227(1-2):407-415. 10.1111/j.1432-1033.1995.tb20403.x, 7851415.
15. Nakajima K, Hamanoue M, Takemoto N, Hattori T, Kato K, Kohsaka S. Plasminogen binds specifically to alpha-enolase on rat neuronal plasma membrane. J Neurochem 1994, 63(6):2048-2057.
16. Miles LA, Dahlberg CM, Plescia J, Felez J, Kato K, Plow EF. Role of cell-surface lysines in plasminogen binding to cells: identification of alpha-enolase as a candidate plasminogen receptor. Biochemistry 1991, 30(6):1682-1691. 10.1021/bi00220a034, 1847072.
17. Dudani AK, Cummings C, Hashemi S, Ganz PR. Isolation of a novel 45 kDa plasminogen receptor from human endothelial cells. Thromb Res 1993, 69(2):185-196. 10.1016/0049-3848(93)90044-O, 8383363.
18. Altenberg B, Greulich KO. Genes of glycolysis are ubiquitously overexpressed in 24 cancer classes. Genomics 2004, 84(6):1014-1020. 10.1016/j.ygeno.2004.08.010, 15533718.
19. Chang GC, Liu KJ, Hsieh CL, Hu TS, Charoenfuprasert S, Liu HK, Luh KT, Hsu LH, Wu CW, Ting CC, et al. Identification of alpha-enolase as an autoantigen in lung cancer: its overexpression is associated with clinical outcomes. Clin Cancer Res 2006, 12(19):5746-5754. 10.1158/1078-0432.CCR-06-0324, 17020980.
20. Hennipman A, van Oirschot BA, Smits J, Rijksen G, Staal GE. Glycolytic enzyme activities in breast cancer metastases. Tumour Biol 1988, 9(5):241-248. 10.1159/000217568, 2973647.
21. Peebles KA, Duncan MW, Ruch RJ, Malkinson AM. Proteomic analysis of a neoplastic mouse lung epithelial cell line whose tumorigenicity has been abrogated by transfection with the gap junction structural gene for connexin 43, Gja1. Carcinogenesis 2003, 24(4):651-657. 10.1093/carcin/bgg008, 12727792.
22. Tsai ST, Chien IH, Shen WH, Kuo YZ, Jin YT, Wong TY, Hsiao JR, Wang HP, Shih NY, Wu LW. ENO1, a potential prognostic head and neck cancer marker, promotes transformation partly via chemokine CCL20 induction. Eur J Cancer 2010, 46(9):1712-1723. 10.1016/j.ejca.2010.03.018, 20435467.
23. Wu W, Tang X, Hu W, Lotan R, Hong WK, Mao L. Identification and validation of metastasis-associated proteins in head and neck cancer cell lines by two-dimensional electrophoresis and mass spectrometry. Clin Exp Metastasis 2002, 19(4):319-326. 10.1023/A:1015515119300, 12090472.
24. Zhang L, Cilley RE, Chinoy MR. Suppression subtractive hybridization to identify gene expressions in variant and classic small cell lung cancer cell lines. J Surg Res 2000, 93(1):108-119. 10.1006/jsre.2000.5957, 10945951.
25. Takashima M, Kuramitsu Y, Yokoyama Y, Iizuka N, Fujimoto M, Nishisaka T, Okita K, Oka M, Nakamura K. Overexpression of alpha enolase in hepatitis C virus-related hepatocellular carcinoma: association with tumor progression as determined by proteomic analysis. Proteomics 2005, 5(6):1686-1692. 10.1002/pmic.200401022, 15800975.
26. Takikita M, Altekruse S, Lynch CF, Goodman MT, Hernandez BY, Green M, Cozen W, Cockburn M, Sibug Saber M, Topor M, et al. Associations between selected biomarkers and prognosis in a population-based pancreatic cancer tissue microarray. Cancer Res 2009, 69(7):2950-2955. 10.1158/0008-5472.CAN-08-3879, 2711977, 19276352.
27. Tu SH, Chang CC, Chen CS, Tam KW, Wang YJ, Lee CH, Lin HW, Cheng TC, Huang CS, Chu JS, et al. Increased expression of enolase alpha in human breast cancer confers tamoxifen resistance in human breast cancer cells. Breast Cancer Res Treat 2010, 121(3):539-553. 10.1007/s10549-009-0492-0, 19655245.
28. Hamaguchi T, Iizuka N, Tsunedomi R, Hamamoto Y, Miyamoto T, Iida M, Tokuhisa Y, Sakamoto K, Takashima M, Tamesa T, et al. Glycolysis module activated by hypoxia-inducible factor 1alpha is related to the aggressive phenotype of hepatocellular carcinoma. Int J Oncol 2008, 33(4):725-731.
29. Racz A, Brass N, Hofer M, Sybrecht GW, Remberger K, Meese EU. Gene amplification at chromosome 1pter-p33 including the genes PAX7 and ENO1 in squamous cell lung carcinoma. Int J Oncol 2000, 17(1):67-73.
30. He P, Naka T, Serada S, Fujimoto M, Tanaka T, Hashimoto S, Shima Y, Yamadori T, Suzuki H, Hirashima T, et al. Proteomics-based identification of alpha-enolase as a tumor antigen in non-small lung cancer. Cancer Sci 2007, 98(8):1234-1240. 10.1111/j.1349-7006.2007.00509.x, 17506794.
31. Tiseo M, Ardizzoni A, Cafferata MA, Loprevite M, Chiaramondia M, Filiberti R, Marroni P, Grossi F, Paganuzzi M. Predictive and prognostic significance of neuron-specific enolase (NSE) in non-small cell lung cancer. Anticancer Res 2008, 28(1B):507-513.
32. Misdorp W, Else RW, Hellmén E, Lipscomb TP. Histological Classification of Mammary Tumors of the Dog and Cat. 1999, Washington, D. C.: American Registry of Pathology.
33. Owen LN. The TNM Classification of Tumors in Domestic Animals. 1980, Geneva: World Health Organization, First.
34. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991, 19(5):403-410. 10.1111/j.1365-2559.1991.tb00229.x, 1757079.
35. Karayannopoulou M, Kaldrymidou E, Constantinidis TC, Dessiris A. Histological grading and prognosis in dogs with mammary carcinomas: application of a human grading method. J Comp Pathol 2005, 133(4):246-252. 10.1016/j.jcpa.2005.05.003, 16202421.
36. Charafe-Jauffret E, Tarpin C, Bardou VJ, Bertucci F, Ginestier C, Braud AC, Puig B, Geneix J, Hassoun J, Birnbaum D, et al. Immunophenotypic analysis of inflammatory breast cancers: identification of an 'inflammatory signature'. J Pathol 2004, 202(3):265-273. 10.1002/path.1515, 14991891.
37. Briffod M, Hacene K, Le Doussal V. Immunohistochemistry on cell blocks from fine-needle cytopunctures of primary breast carcinomas and lymph node metastases. Mod Pathol 2000, 13(8):841-850. 10.1038/modpathol.3880149, 10955449.
38. Li J, Martinka M, Li G. Role of ING4 in human melanoma cell migration, invasion and patient survival. Carcinogenesis 2008, 29(7):1373-1379. 10.1093/carcin/bgn086, 18375955.
39. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007, 25(1):118-145.